ULTOMIRIS® (ravulizumab‑cwvz)

Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020

Retrieved on: 
Friday, October 9, 2020
Biotechnology, General Health, Pharmaceutical, Health, Health, Medical specialties, Clinical medicine, Blood disorders, Orphan drugs, Alexion Pharmaceuticals, Atypical hemolytic uremic syndrome, Eculizumab, Ahus, Ravulizumab, Hemolysis, Hemolytic–uremic syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), ULTOMIRIS® (ravulizumab‑cwvz), SOLIRIS® (eculizumab), Alexion

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that four abstracts have been accepted for presentation at the American Society of Nephrologys Kidney Week 2020, taking place virtually from October 22 to 25, 2020.

Key Points: 
  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that four abstracts have been accepted for presentation at the American Society of Nephrologys Kidney Week 2020, taking place virtually from October 22 to 25, 2020.
  • Alexion also plans to present on the comparative efficacy of ULTOMIRIS and SOLIRIS in the treatment of adults with aHUS.
  • Efficacy and Safety of Ravulizumab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome Previously Treated with Eculizumab: 26week and 1year Data.
  • Comparative Efficacy of Ravulizumab and Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome: An Indirect Comparison Using Clinical Trial Data.

Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint

Retrieved on: 
Wednesday, June 24, 2020
Pharmaceutical, Health, Clinical trials, Medical devices, Monoclonal antibodies, Biotechnology, Life sciences, Alexion Pharmaceuticals, PNH, Paroxysmal nocturnal hemoglobinuria, Ravulizumab, Pharmaceutical industry, the Phase 3 Study, ULTOMIRIS SC Delivery, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), ULTOMIRIS® (ravulizumab‑cwvz), Alexion

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced topline results from a Phase 3 study of weekly self-administered subcutaneous (SC) ULTOMIRIS (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Key Points: 
  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced topline results from a Phase 3 study of weekly self-administered subcutaneous (SC) ULTOMIRIS (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • The ongoing study met its primary objective of pharmacokinetic (PK)-based non-inferiority of ULTOMIRIS SC versus intravenous (IV) ULTOMIRIS at Day 71.
  • This ongoing global Phase 3, randomized, open-label, parallel-group, multicenter study is evaluating ULTOMIRIS SC compared with ULTOMIRIS IV.
  • The study met its primary objective, with ULTOMIRIS SC demonstrating PK-based non-inferiority versus ULTOMIRIS IV at Day 71 (p